The FY23 TBIPHRP TRA is intended to support translational research that will accelerate the movement of promising ideas in psychological health conditions and/or TBI research into clinical applications, including health care products, technologies, and/or clinical practice guidelines.
Applicants should not view translational research as a one-way continuum from bench to bedside. The research plan is encouraged to involve a reciprocal flow of ideas and information between applied and clinical research. As such, applications must include preliminary and/or published data to support the proposed research project.
Applications to the FY23 TBIPHRP TRA may include preclinical and/or clinical research involving human subjects and human anatomical substances. The FY23 TBIPHRP TRA may also support ancillary studies that are associated with an ongoing or completed clinical trial and projects that optimize the design of future clinical trials.
Deadlines:
• Required Pre-Application Deadline: June 8, 2023
• Application Submission Deadline: July 6, 2023
Independent investigators at all academic/career levels (or equivalent) may be named by organizations as the PI on the application. Postdoctoral fellows are not considered independent investigators unless documentation is provided by the applicant’s organization.
Early-Career Investigator Partnering Option: The Early-Career Investigator must be an independent investigator within 10 years after completion of their terminal degree by the time of the application submission deadline (excluding time spent in residency or on family medical leave). Time spent as a postdoctoral fellow is not excluded. Postdoctoral fellows are not considered independent investigators unless documentation is provided by the applicant’s organization. Lapses in research time or appointments as denoted in the biographical sketch should be explained in the application. For Early-Career Investigator Partnering Option applications, at least one of the named PIs must be an Early-Career Investigator.
The anticipated direct costs budgeted for the entire period of performance for an FY23 TBIPHRP TRA should not exceed $1.0M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.
